ANDREW C. ORTH - 28 Feb 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Commercial Officer
Signature
/s/ Andrew Orth
Issuer symbol
KRYS
Transactions as of
28 Feb 2022
Net transactions value
$0
Form type
4
Filing time
01 Mar 2022, 20:22:58 UTC
Previous filing
02 Jun 2021
Next filing
28 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KRYS Common Stock 100 28 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 28 Feb 2022 Common Stock 50,000 $63.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in four equal annual installments beginning on February 28, 2023.